Rational Drug Repurposing: Focus on Lysosomotropism, Targets in Disease Process, Drug Profile, and Pulmonary Tissue Accumulation in SARS-CoV-2 Infection/COVID-19

Markus Blaess; Lars Kaiser; Oliver Sommerfeld; Simone Rentschler; René Csuk; Hans-Peter Deigner

doi:10.3389/fphar.2020.584881

Rational Drug Repurposing: Focus on Lysosomotropism, Targets in Disease Process, Drug Profile, and Pulmonary Tissue Accumulation in SARS-CoV-2 Infection/COVID-19

Front Pharmacol. 2020 Nov 20:11:584881. doi: 10.3389/fphar.2020.584881. eCollection 2020.

Authors

Markus Blaess¹, Lars Kaiser^{1

2}, Oliver Sommerfeld³, Simone Rentschler¹, René Csuk⁴, Hans-Peter Deigner^{1

5

6}

Affiliations

¹ Institute of Precision Medicine, Medical and Life Sciences Faculty, Furtwangen University, Villingen-Schwenningen, Germany.
² Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg, Germany.
³ Department of Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany.
⁴ Department of Organic Chemistry, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
⁵ EXIM Department, Fraunhofer Institute IZI Leipzig, Rostock, Germany.
⁶ Faculty of Science, Tuebingen University, Tübingen, Germany.

No abstract available

Keywords: COVID-19; SARS-CoV-2; approved active compounds; cytokine storm syndrome; lysosome; lysosomotropic compounds; lysosomotropism; repurposing approved drugs.